Cannabis News NORML - Working to Reform Marijuana Laws
  Marijuana Compound Spurs Brain Cell Growth
Posted by CN Staff on October 13, 2005 at 14:25:48 PT
By Alan Mozes, HealthDay Reporter  
Source: Forbes Magazine  

medical HealthDay News -- When it comes to the controversy surrounding medical marijuana, an international team of researchers is busy stirring the pot by releasing findings that suggest the drug helps promote brain cell growth while treating mood disorders.

According to the study in rats, a super-potent synthetic version of the cannabinoid compound found in marijuana can reduce depression and anxiety when taken over an extended period of time.

This mood boost seems to be the result of the drug's ability to promote the growth of new brain cells, something no other addictive drug appears able to do, the researchers say.

The findings, which appear in the November issue of the Journal of Clinical Investigation, remain preliminary, however.

"Our results were obtained from rats, and there's a big difference between rats and humans," said study co-author Dr. Xia Zhang, of the neuropsychiatry research unit in the department of psychiatry at the University of Saskatchewan in Saskatoon, Canada. "So, I don't really don't know yet if our findings apply to humans. But our results indicate that the clinical use of marijuana could make people feel better by helping control anxiety and depression."

The new findings come on the heels of a U.S. Supreme Court ruling in June granting federal authorities the power to stop doctors from prescribing marijuana. That decision also bars individuals from cultivating the herb for medical purposes.

The decision overrides laws currently on the books in 11 states which had legalized the use of marijuana for patients receiving a doctor's approval. According to the ruling, the Supreme Court justices made their decision on the basis of interstate commerce regulations rather than on an evaluation of the pros and cons of medical marijuana use.

But does medical marijuana work? To help settle that question, Zhang's team focused on the potential of a synthetic laboratory-produced form of the cannabinoid compound naturally found in the marijuana plant.

Humans and other animals also naturally produce the compound, and are known to have cannabinoid receptors lying on the surface of cells in the nervous system and the immune system.

Prior research has shown that, when exposed to cannabinoids, these receptors can provoke an anti-inflammatory and anti-convulsive response. They can also instigate a range of psychotropic effects such as euphoria.

The current study focused on a particular formulation of synthetic cannabinoid known as HU210 -- a compound which Zhang described as the most powerful cannabinoid in the world.

The authors explored both the short-term and long-term effects of exposure to HU210 in rats.

To measure the drug's short-term response, they gave adult rats a single injection of HU210. To study the same drug's effect over the longer term, the researchers gave a separate group of adult rats twice-daily injections of the cannabinoid over a two-week period.

Autopsies revealed that by the end of the 10-day HU210 treatment regimen, new neurons had been generated and integrated into the circuitry of the hippocampus region of the rat's brains. This process, known as neurogenesis, was still in evidence a full month after treatment had been initiated.

Neurogenesis was not triggered in response to brain cells being killed through cannabinoid exposure, the researchers add. In fact, HU210 injections did not appear to prompt any loss of neurons in the hippocampus.

Cannabinoid use appeared to boost mood, as well: According to the scientists, behavioral tests suggest that long-term treatment reduced the rodent's anxiety- and depression-linked behaviors.

For example, one month post-treatment, treated rats deprived of food for 48 hours were quicker than similarly deprived, non-treated rats to begin eating food when it was finally offered to them in an unfamiliar environment.

The researchers believe treated rats may have been less anxious in the manner they handled this novel situation. They stress the results were not related to cannabinoids' appetite-stimulating effects, since the treated rats' eating behavior was similar to that of untreated rats when they were offered food in a familiar setting.

Treated rats also responded in a less anxious manner to swimming and climbing tests, and displayed shorter periods of immobility compared with untreated rats. The latter finding was interpreted to mean that HU210 had an antidepressant effect on rats receiving the cannabinoid over the longer term.

However, while long-term administration of higher doses worked to reduce anxiety and depression, lower doses did not appear to have the same effect, the researchers added.

Zhang and his associates credit cannabinoid-linked neurogenesis with the apparent mood shifts seen in the animals.

The hippocampus area of the brain where the neuronal growth occurred is key to the regulation of stress and other mood disorders, Zhang's team point out. This region is also important to the control of cognitive processes such as learning and memory.

Among the common addictive drugs, marijuana alone appears able to promote neurogenesis when used over time and in the right dosage, the researchers say. In contrast, prior research has demonstrated that chronic administration of cocaine, opiates, alcohol and nicotine inhibits brain cell growth.

"If our results can be confirmed in humans, we should anticipate the chronic use of marijuana as a medical treatment for anxiety and depression," Zhang said.

However, he cautioned that "this treatment is not the same as smoking marijuana. Whether smoking marijuana can produce the same effect, we just don't know."

Dr. Perry G. Fine, a professor of anesthesiology at the University of Utah School of Medicine Pain Research Center, said more than enough data has already been gathered to confirm medical marijuana's potential benefits.

"It's great that there's new science, but to me this is no longer an epiphany," he said. "It's just proving what's been long-suspected. We're behind the curve with the cannabinoids largely because of the stigma of marijuana going years and years back."

"I think most people with clinical expertise in the area of palliative medicine know that if patients had access to all the tools we currently have, we could certainly do a whole lot better to help people live with multiple chronic diseases," he added. "The social policies are way behind our technology, and that's where we need some catching up."

More information:

For more on the medical marijuana debate, check out: http://www.medicalmarijuanaprocon.org/pop/conflicts.htm

Source: Forbes Magazine (US)
Author: Alan Mozes, HealthDay Reporter
Published: October 13, 2005
Copyright: 2005 Forbes Inc.
Contact: readers@forbes.com
Website: http://www.forbes.com/

CannabisNews Medical Marijuana Archives
http://cannabisnews.com/news/list/medical.shtml


Home    Comment    Email    Register    Recent Comments    Help

 
Comment #8 posted by dongenero on October 14, 2005 at 08:03:13 PT
HU210
Wow, HU210 is $99 dollars for 5mg! So, what would this treatment cost? If 5mg a day would be the dosage, we're talking $3000 dollars per month! Ouch.

Well, as long as some Big Pharma is making money hand over fist, it will probably become a "valid" treatment....as opposed to whole plant.

[ Post Comment ]

 
Comment #7 posted by Sam Adams on October 14, 2005 at 06:55:13 PT
No kidding EJ
That was my thought too - the rats get their anxiety relieved with cannabis, while the thugs throw Steve Tuck, disabled veteran of the US Army, into a jail cell.

[ Post Comment ]
 
Comment #6 posted by CorvallisEric on October 14, 2005 at 04:37:53 PT
HU210
If anyone's curious, here's the catalog page on HU210 with molecular structure, price, and DEA notice: http://www.tocris.com/dispprod.php?ItemId=2257

[ Post Comment ]
 
Comment #5 posted by Toker00 on October 14, 2005 at 03:51:29 PT
I'll confirm it.
"If our results can be confirmed in humans, we should anticipate the chronic use of marijuana as a medical treatment for anxiety and depression," Zhang said.

I'm way ahead of ya.

Wage peace on war. END CANNABIS PROHIBITION NOW!

[ Post Comment ]

 
Comment #4 posted by FoM on October 13, 2005 at 15:25:03 PT
You Go Girl!
You tell them EJ!

[ Post Comment ]
 
Comment #3 posted by E_Johnson on October 13, 2005 at 15:20:22 PT
And this clever fellow has foreseen the past
"If our results can be confirmed in humans, we should anticipate the chronic use of marijuana as a medical treatment for anxiety and depression," Zhang said.

***********************************************

That's already happening, so it's long past the anticipation stage.

What we should anticipate is the end of the verbal and physical abuse of those who already use it as such, dude.



[ Post Comment ]

 
Comment #2 posted by E_Johnson on October 13, 2005 at 15:17:07 PT
The sequence of headlines is suggestive
Drug Agents Can't Keep Up With Pot Growers

Marijuana Compound Spurs Brain Cell Growth

No wonder the drug warriors in DC refuse to play softball with the MPP.



[ Post Comment ]

 
Comment #1 posted by FoM on October 13, 2005 at 14:26:58 PT
Marijuana Compound Spurs Brain Cell Growth
Just think of all the benefits from the whole natural plant.

[ Post Comment ]

  Post Comment
Name:        Password:
E-Mail:

Subject:

Comment:   [Please refrain from using profanity in your message]

Link URL:
Link Title:


Return to Main Menu


So everyone may enjoy this service and to keep it running, here are some guidelines: NO spamming, NO commercial advertising, NO flamming, NO illegal activity, and NO sexually explicit materials. Lastly, we reserve the right to remove any message for any reason!

This web page and related elements are for informative purposes only and thus the use of any of this information is at your risk! We do not own nor are responsible for visitor comments. In accordance with Title 17 U.S.C. Section 107 and The Berne Convention on Literary and Artistic Works, Article 10, news clippings on this site are made available without profit for research and educational purposes. Any trademarks, trade names, service marks, or service names used on this site are the property of their respective owners. Page updated on October 13, 2005 at 14:25:48